Literature DB >> 12721940

Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection.

Michael R Batzloff1, Wendy A Hayman, Mark R Davies, Ming Zeng, Sumalee Pruksakorn, Evelyn R Brandt, Michael F Good.   

Abstract

A conformationally constrained, minimally conserved peptide from the M protein of group A streptococcus (GAS) has been defined. It consists of 12 amino acids from the C-repeat region within a non-M protein helix-forming sequence and is referred to as "J8." Here, we investigate the immunogenicity of a J8-diphtheria toxoid (DT) conjugate adjuvanted with the human-compatible adjuvants, SBAS2 and alum, and demonstrate that it is capable of inducing opsonic antibodies and can protect outbred mice from virulent challenge. In a range of experiments, protection correlated with the titer of J8-specific antibodies and not with the induction of J8-specific T cells. However, DT-specific antibodies (as well as J8-specific antibodies) were shown to stain the surface of fixed GAS and to be capable of opsonizing live organisms. DT may be an ideal carrier protein for J8 and other GAS peptides for GAS vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721940     DOI: 10.1086/374800

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  60 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Strategies in the development of vaccines to prevent infections with group A streptococcus.

Authors:  Michael F Good; Michael R Batzloff; Manisha Pandey
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

3.  Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.

Authors:  Patricia Therese Campbell; Hannah Frost; Pierre R Smeesters; Joseph Kado; Michael F Good; Michael Batzloff; Nicholas Geard; Jodie McVernon; Andrew Steer
Journal:  Vaccine       Date:  2018-11-03       Impact factor: 3.641

4.  Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.

Authors:  Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

Review 5.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 7.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

8.  emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development.

Authors:  Andrew C Steer; Graham Magor; Adam W J Jenney; Joseph Kado; Michael F Good; David McMillan; Michael Batzloff; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2009-06-10       Impact factor: 5.948

9.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.